Tag Archives: Vedanta Biosciences

← Older posts

Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More

Gilead Sciences CEO Daniel O’Day has spoken openly about acquisitions as a way to build up the company’s drug pipeline. This week, it made its biggest buy yet. The $21 billion Immunomedics acquisition brings to Gilead a cancer drug that many analysts project will become a blockbuster seller. Some of those analysts think Gilead might […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Philadelphia Blog Main, Philadelphia Top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More

Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More

At the start of 2020 thousands of biotechies anticipated spending the second week of June in San Diego, hobnobbing at the annual conference hosted by the Biotechnology Innovation Organization. Instead, attendees from 64 countries spanning 28 times zones convened online this week for the first-ever virtual BIO International Convention. There, topics once as unanticipated as the […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Philadelphia Blog Main, Philadelphia Top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More

Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19)

The start of a potentially big biomedical breakthrough is blooming within all of us. Drug research aiming to turn bacteria into microbiome therapies now spans programs aiming to address gut disorders, autism, cancer, and more. Given the number of late-stage and mid-stage studies expected to report data in 2020—assuming they stay on track amid the […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19)

With Yale Tech and $12M, Artizan Aims for Root Cause of Gut Disease

A number of startups are targeting the gut microbiome as a way to potentially treat disease, but identifying specific microbes at the root of illness is a challenge. Although software that analyzes troves of biological data helps, the trillions of gut microbes make the research like looking for a needle in a haystack, says James […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, Raleigh-Durham blog main, Raleigh-Durham top stories, San Francisco blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on With Yale Tech and $12M, Artizan Aims for Root Cause of Gut Disease

With $35M, Whole Biome Eyes 2020 Launch of Medical Food for Diabetes

Diabetes treatments available today include shots and pills intended to restore the hormone balance that leads to healthy blood sugar levels. Whole Biome aims to accomplish the same thing—but with a capsule that targets the gut microbiome. Whole Biome is preparing to launch its product early next year. To support those plans, the San Francisco-based […]

Posted in Boston blog main, National blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on With $35M, Whole Biome Eyes 2020 Launch of Medical Food for Diabetes

Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More

Generic drugs are supposed to give consumers more choices and a counterweight to more costly branded medications. During his tenure as FDA commissioner, Scott Gottlieb often spoke about generics as a market force that could help tame climbing drug prices. But such tools only work when companies play fair. A lawsuit is now claiming that […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More

Gates Foundation, Bristol-Myers Join $27M Funding for Vedanta Bio

Microbiome drug developer Vedanta Biosciences has raised $27 million in funding to press forward with clinical trials for four therapeutic candidates. Vedanta’s experimental treatments are compositions of live bacteria that the Cambridge, MA, company says trigger a targeted immune response. By shifting the ecosystem of gut bacteria, Vedanta says its therapies can potentially treat autoimmune […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, San Francisco blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Gates Foundation, Bristol-Myers Join $27M Funding for Vedanta Bio

Microbiome Startup uBiome Expands into Drug Research with $83M

Biotech company uBiome started as a “citizen science” project that collected and studied microbiome samples in order to learn how the trillions of bacteria living in and on people’s bodies affect human health. Six years and 250,000 samples later, uBiome is now moving beyond simply helping people understand their microbiomes. The San Francisco company has […]

Posted in Boston blog main, Boston top stories, National blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , | Comments Off on Microbiome Startup uBiome Expands into Drug Research with $83M

FDA Turmoil, Biology Mystery On List Of Hurdles For Microbiome Drugs

In three years, investment has jumped more than twenty-fold in startups developing medicines that change the interactions between our bodies and the bacteria that colonize it, known collectively as the human microbiome. But as a panel of industry insiders noted yesterday at the BIO CEO & Investor Conference Monday, the field faces several challenges—including lack […]

Posted in Boston blog main, Boston top stories, Detroit blog main, Detroit top stories, National blog main, National top stories, New York, New York blog main, New York top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , | Comments Off on FDA Turmoil, Biology Mystery On List Of Hurdles For Microbiome Drugs

Bio Roundup: Precision Med and Google, Heron, Lilly, Sarepta & More

The wait continues. An FDA ruling on a Duchenne muscular dystrophy drug from Sarepta Therapeutics—which could be the first ever approved for the disease—has been imminent for a while now, yet Labor Day is fast approaching and still the saga drags on. Speculation abounds, from analysts and pundits, each giving different opinions as to whether […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Detroit blog main, Indiana blog main, National, National blog main, National top stories, New York blog main, Raleigh-Durham blog main, San Diego blog main, San Francisco blog main, San Francisco top stories, Seattle blog main, Texas blog main, Wisconsin blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Precision Med and Google, Heron, Lilly, Sarepta & More← Older posts